|
J Biol Chem, Vol. 275, Issue 14, 10278-10284, April 7, 2000
Regulation of mOAT-mediated Organic Anion Transport by Okadaic
Acid and Protein Kinase C in LLC-PK1 Cells*
Guofeng
You §,
Kogo
Kuze ,
Ronald A.
Kohanski¶,
Kurt
Amsler , and
Scott
Henderson**
From the Departments of Medicine, ¶ Biochemistry
and Molecular Biology, and ** Anatomy and Cell Biology, Mount Sinai
School of Medicine, New York, New York 10029 and the Department
of Physiology and Biophysics, University of Medicine and Dentistry of
New Jersey-Robert Wood Johnson Medical School,
Piscataway, New Jersey 08854-5635
 |
ABSTRACT |
Organic anion transporters in the kidney proximal
tubule play an essential role in eliminating a wide range of organic
anions including endogenous compounds, xenobiotics, and their
metabolites, thereby preventing their potentially toxic effects within
the body. We have previously cloned a cDNA encoding an organic anion transporter from mouse kidney (mOAT) (Lopez-Nieto, C. E., You, G.,
Bush, K. T., Barros, E. J. G., Beier, D. R., and Nigam, S. K. (1997)
J. Biol. Chem. 272, 6471-6478; Kuze, K., Graves, P., Leahy, A., Wilson, P., Stuhlmann, H., and You, G. (1999) J. Biol. Chem. 274, 1519-1524). In the present study, we assessed the
potential for regulation of this transporter by heterologous expression of mOAT in the pig proximal tubule-like cell line, LLC-PK1.
We report here that both protein phosphatase (PP1/PP2A) inhibitor, okadaic acid, and protein kinase C (PKC) activators down-regulate mOAT-mediated transport of para-aminohippuric acid (PAH), a
prototypic organic anion, in a time- and concentrationdependent
manner. However their mechanisms of action for this down-regulation are
distinct. Okadaic acid modulated PAH transport, at least in part,
through phosphorylation/dephosphorylation of mOAT; phosphoamino acid
analysis indicated this phosphorylation occurs on serine. In contrast, PKC activation induced a decrease in the maximum transport velocity (Vmax) of PAH transport without direct
phosphorylation of the transporter protein. Together these results
provide the first demonstration that regulation of organic anion
transport by mOAT is likely to be tightly controlled directly and
indirectly by phosphatase PP1/PP2A and PKC. Our results also suggest
that kinases other than PKC are involved in this process.
 |
INTRODUCTION |
Renal organic anion transport plays a vital role in the
elimination of a wide variety of potentially toxic and negatively charged waste products of metabolism, drugs, environmental pollutants, and their metabolites from the body. The transport mechanisms responsible for this elimination have been extensively studied (3-5).
Based on these studies, it has been suggested that the transport of
organic anions is a complex process involving distinctly different
proteins at the apical and basolateral membranes of the proximal tubule
cells. Organic anions are transported across the basolateral
membrane into the cell in exchange for intracellular dicarboxylates,
which are subsequently returned into the cell via a
sodium-dependent dicarboxylate transporter. Once inside the
cell, organic anions are subject to intracellular binding and
sequestration within vesicular structures. Finally, luminal exit is
thought to occur by anion exchange and/or facilitated diffusion
(3-5).
We (1, 2) and others (6-11) have recently cloned the organic anion
transporter cDNA from kidneys of multiple species. Using computer
modeling based on hydropathy analysis, the predicted proteins share
several common features, including 12 putative membrane-spanning
segments, a cluster of potential glycosylation sites located in the
first extracellular loop between transmembrane domains 1 and 2, and
multiple presumptive phosphorylation sites. Recent progress from our
laboratory on the study of structure/function relationships in
mOAT1 using heterologous
expression systems has shown that histidine residues are important for
the transport function, and glycosylation is necessary for the
targeting of mOAT to the plasma membrane (2).
The presence of potential phosphorylation sites on these proteins
suggests that they may be subject to phosphorylation-induced functional
regulation, and several studies have indicated that transport of
organic anions is affected by PKC activators (9, 12-15). In this
report we provide the first evidence that the phosphatase inhibitor,
okadaic acid, and PKC activators both modulate mOAT-mediated transport
function. However, their mechanisms of action are distinct. Okadaic
acid regulates the transport, at least in part, through the
phosphorylation of serine residue(s) of mOAT, whereas PKC modulates the
transport function by changing the maximum transport velocity without
direct phosphorylation of the tranporter protein. We also suggest that
kinases other than PKC are involved in the regulation of organic anion transport.
 |
EXPERIMENTAL PROCEDURES |
Materials--
[32P]Orthophosphate was obtained
from ICN. Protease inhibitor complex was from Roche Molecular
Biochemicals. Protein A-agarose beads were from Life Technologies, Inc.
Phosphoamino acid standards (Ser(P), Thr(P), and Tyr(P)) were from
Sigma. Phorbol 12-myristate 13-acetate (PMA), phorbol 12,13-dibutyrate
(PDBu), 4 -phorbol 12,13-didecanoate (4 -PDD),
1-oleoyl-2-acetyl-sn-glycerol (OAG), and indolactam were
also purchased from Sigma.
Construction of myc-tagged mOAT cDNA--
Full-length
cDNA encoding mOAT with the c-myc epitope tag, was subcloned into
the mammalian expression vector pcDNA3.1( ). The epitope-tagged
constructs encoded a fusion protein consisting of full-length mOAT with
10 amino acids of the human c-Myc epitope (EQKLISEEDL, nucleotide
sequence GAACAAAAGCTGATTTCTGAAGAAGACCTG) at the carboxyl terminus.
Tagged mOAT cDNA was synthesized by polymerase chain reaction
amplification. The polymerase chain reaction product was subcloned into
the plasmid pcDNA3.1( ) at XbaI and HindIII
sites. The nucleotide sequence was confirmed by the dideoxy
chain-termination sequencing method (16).
Generation of LLC-PK1 Cells Expressing mOAT and
mOAT-myc--
LLC-PK1 cells purchased from the American
Type Culture Collection were grown in Dulbecco's modified Eagle's
medium (DMEM) supplemented with 10% fetal bovine serum, in a 5%
CO2 atmosphere at 37 °C. LLC-PK1 cells were seeded at
1 × 106/100-mm dish/10 ml of complete medium 24 h before transfection. For transfection a DNA-calcium phosphate
precipitate (1 ml) formed with 20 µg in total of plasmid DNA was
added and the cells were incubated at 37 °C for 24 h, washed,
and incubated further. After 14-20 days of selection in medium
containing 2 mg/ml Geneticin (G418; Life Technologies, Inc.) following
the manufacturer's instruction, resistant colonies were replated to 96 wells for cloning, expanded, and used for analyzing positive clones.
Cell Culture--
LLC-PK1 cells expressing mOAT or
mOAT-myc established above were maintained in complete medium
consisting of DMEM supplemented with 10% fetal bovine serum.
Monolayers were grown under an atmosphere of 5% CO2, 95%
air at 37 °C, and were subcultured every 2-3 days using 0.02% EDTA
and 0.05% trypsin. For the transport assay, confluent cell monolayers
were cultured in Transwell chambers (0.4-µm pores) in 12-well plates
(Costar, Cambridge, MA). The volume of medium inside and outside the
chambers was 0.5 and 1.5 ml, respectively.
Transport Measurements--
Uptake of [14C]PAH was
initiated by adding uptake solution (PBS, pH 7, containing 5 mM glucose and [14C]PAH) to either the basal
or apical side of the monolayers. At times as indicated in the figure
legends, the uptake was stopped by rapidly washing the cells with
ice-cold PBS. The cells were then solubilized in 0.2 N NaOH
and aliquoted for liquid scintillation counting. Uptake count was
standardized by the amount of protein in each well. Values were
mean ± S.E. (n = 3).
Northern Blot Analysis--
Five µg of total RNA prepared from
stable transfectant clones was electrophoresed on a 1%
agarose/formaldehyde gel and transferred to nitrocellulose. The
membrane was hybridized at 42 °C overnight in hybridization solution
with full-length mOAT cDNA labeled with [32P]dCTP by
random primer labeling, followed by purification using a Sephadex G-50
spin-column (Amersham Pharmacia Biotech). The filter was washed in
0.2× SSC, 0.1% SDS at 65 °C and subjected to autoradiography.
Cell Membrane Isolation--
Cells grown on a 100-mm dish were
homogenized in isolation solution (250 mM sucrose, 10 mM triethanolamine, pH 7.6) containing complete protease
inhibitor mixture (Roche Molecular Biochemicals). Crude membranes were
obtained by centrifuging at 1000 × g for 10 min at
4 °C, discarding the pellet, and centrifuging the supernatant at
17,000 × g at 4 °C for 20 min. The resulting pellet
was resuspended in isolation solution plus protease inhibitors.
Electrophoresis and Immunoblotting--
Protein samples were
loaded (20 µg/lane) on 7.5% SDS-PAGE minigels and electrophoresed
using a mini cell (Bio-Rad). Proteins were transferred to PVDF
membranes in an electroelution cell (Bio-Rad). The blots were blocked
for 1 h with 5% nonfat dry milk in PBS-Tween (80 mM
Na2HPO4, 20 mM
NaH2PO4,100 mM NaCl, 0.1% Tween
20, pH 7.5), washed, and incubated for 1 h at room temperature
with anti-Myc monoclonal antibody (1:400). The membranes were washed,
incubated with goat anti-mouse IgG conjugated to horseradish peroxidase (1:5000), and signals were detected by enhanced chemiluminescence (ECL; Amersham).
Confocal Laser Scanning Microscopy--
Cells were examined
using a Leica TCS-SP (UV) confocal laser scanning microscope
(Heidelberg, Germany) equipped with a 100 × 1.4 numeric aperture
objective lens. The pinhole size was adjusted such that resultant
"optical sections" were approximately 0.5 µm in thickness. Images
were collected in the xy plane (from serial optical sections
generated at 0.5-µm intervals from the top to the bottom of the
cells) or in the xz plane.
The sensitivity of the photomultiplier detectors was set such that the
intensity levels of the output signal in the plane of maximum
fluorescence intensity were distributed in a linear fashion (via a glow
over/under lookup table) over 256 gray levels (with the dimmest pixel,
black = 0 and the brightest pixel, white = 255). For control
studies (in which the primary antibody was omitted), the detector
settings were maintained at the values used in the studies in which
primary antibody was present.
Metabolic Labeling and Immunoprecipitation--
Stably
transfected LLC-PK1 cells were seeded on six-well plates.
(approximately 2 × 106/well). The cells were washed
once with phosphate-free DMEM without serum or antibiotics and
incubated with 2 ml of this medium at 37 °C for 1 h. The cells
were labeled by addition of 25 µl of 2 mCi/ml
[32P]orthophosphate (50 µCi/well/ml) and incubated for
3 h at 37 °C. Okadaic acid or PKC activators at various
concentrations (see figure legends) were added to the medium, and the
incubation was continued at 37 °C. The treated cells were washed
once with ice-cold PBS. 400 µl of ice-cold RIPA buffer containing
protease and phosphatase inhibitors was added, and the cells were
lysed. RIPA buffer consisted of 10 mM Tris, 150 mM NaCl, 1 mM EDTA, 0.1% SDS, 1% Triton
X-100, 1% sodium deoxycholate, pH 7.4, with the protease inhibitor
complex, and phosphatase inhibitors: 10 mM sodium fluoride
and 1 µM okadaic acid. The lysate was centrifuged at
13,000 × g for 30 min at 4 °C. The supernatant was
precleaned with 100 µl of protein A-agarose beads for 1 h with
shaking at 4 °C. The lysate was centrifuged at 200 × g for 1 min, and the supernatant was incubated with 3 µl
of anti-myc monoclonal antibody at 4 °C overnight, with end-over-end continuous mixing. Then, 20 µl of protein A-agarose beads were added
and the lysate was agitated for 1 h at 4 °C. The lysate was
centrifuged at 200 × g for 1 min, and the pellet was
washed with 400 µl of ice-cold RIPA buffer several times. The pellet was suspended in 60 µl of Laemmli buffer containing
-mercaptoethanol and incubated for 30 min at room temperature. The
samples were boiled for 5 min and loaded onto 7.5% SDS-PAGE mini gels.
The gel was fixed with 10% acetic acid and 50% methanol for 40 min and dried with a vacuum gel drier at 70 °C for 3 h. The
radiolabeled proteins were detected and quantified using a PhosphorImager.
Phosphoamino Acid Analysis--
The conditions for acid
hydrolysis and thin layer separation are taken from Boyle et
al. (17). In vitro phosphorylation of mOAT was done as
described above. The 32P-labeled protein was resolved by
SDS-PAGE and transferred to PVDF. The radiolabeled protein was located
by autoradiography, the band excised, and acid hydrolysis in 6 N HCl was done for 90 min at 120 °C. The PVDF was
removed and the hydrolysate dried in vacuo. The sample was
redissolved in 10 µl of pH 3.5 buffer containing unlabeled
phosphoamino acid standards (Ser(P), Thr(P), and Tyr(P)), and 8 µl
were spotted on a 20 × 20-cm cellulose thin layer plate.
Phosphoamino acids were resolved by two-dimensional high voltage
electrophoresis, for 35 min at 1.2 kV in pH 3.5 buffer, and after
drying the plate, for 25 min at 1.0 kV in pH 1.9 buffer. The standards
were visualized with ninhydrin (Pierce) and the [32P]phosphoamino acids by autoradiography with a PhosphorImager.
 |
RESULTS |
Generation of LLC-PK1 Cells Expressing mOAT and
mOAT-myc--
To make stable mOAT-expressing clones in
LLC-PK1 cells, we cloned the cDNAs, encoding mOAT and
mOAT tagged with a carboxyl-terminal c-Myc epitope, behind the
cytomegalovirus promoter in the mammalian expression vector
pcDNA3.1( ), which contains the neo gene for selection
with G418. After 2 weeks of selection, 5 clones were obtained from cell
populations transfected with the control plasmid (vector alone), 17 clones were obtained from populations transfected pcDNA3.1( )-mOAT
plasmid, and 23 clones were obtained from populations transfected with
pcDNA3.1( )-mOAT-myc plasmid. Preliminary studies measured
[14C]PAH uptake in clones of mOAT-expressing and
mOAT-myc-expressing cells (data not shown). Clones exhibiting high
levels of uptake were chosen for further studies. Northern blot
analysis (Fig. 1a) using
full-length mOAT cDNA as probe confirmed that clones exhibiting
high levels of PAH uptake contained high level of mOAT transcript
(lanes 2 and 3), whereas mOAT
transcript was not detected in LLC-PK1 cells transfected
with vector alone (lane 1). To confirm that these
clones expressed high levels of mOAT protein, Western blot studies were
performed using crude membrane preparations derived from
vector-transfected (control) or mOAT-myc-transfected cells. As shown in
Fig. 1b, membrane proteins derived from vector-transfected cells exhibited no reactivity with the c-myc antibody (lane
1), as expected, but membrane proteins derived from cells
transfected with mOAT-myc cDNA expressed a c-myc antibody-reactive
protein at about 60 kDa (lane 2), consistent with
the predicted molecular mass for mOAT (1).

View larger version (27K):
[in this window]
[in a new window]
|
Fig. 1.
Generation of LLC-PK1 cells
expressing mOAT and mOAT-myc. a, Northern blot analysis
of total RNA isolated from LLC-PK1 cells expressing
pcDNA3.1( ) alone (control, lane 1),
pcDNA3.1( )-mOAT (lane 2), and
pcDNA3.1( )-mOAT-myc (lane 3). b,
Western blot analysis with crude membranes from cells expressing
pcDNA3.1( ) alone (control, lane 1) and
pcDNA3.1( )-mOAT-myc (lane 2). The blot was
probed with anti-myc antibody and horseradish peroxidase-labeled
secondary antibody and visualized by ECL system.
|
|
mOAT Localization in Polarized LLC-PK1 Cells--
We
next examined the localization of mOAT transporter in polarized
LLC-PK1 cells. At confluence, LLC-PK1 cells
form an epithelium with separate apical and basolateral membrane
domains containing different complements of membrane proteins (30). The
mOAT transporter in vivo is expressed exclusively at the
basolateral membrane (31, 32). The uptake of PAH from either the basal
or the apical side was measured in confluent monolayers of cells
transfected with vector alone, mOAT, mOAT-myc. Cells were grown on
permeable membrane filter supports to provide independent access to
either the apical or the basolateral membrane. As shown in Fig.
2a, 20-min uptake of
14C-labeled PAH from the basal side was about 5-fold higher
than that from apical side into cells transfected with mOAT or
mOAT-myc, whereas little uptake was observed in vector
alone-transfected cells. Therefore, mOAT and mOAT-myc were functionally
expressed primarily on the basolateral membrane of polarized
LLC-PK1 cells. The time course for [14C]PAH
uptake at the basolateral surface was compared in vector-transfected and mOAT-myc-transfected cells (Fig. 2b). As expected,
uptake was markedly faster into mOAT-myc-expressing cells. In
mOAT-myc-expressing cells, uptake increased linearly for approximately
2 min and reached a steady state between 5 and 10 min. Therefore, an
uptake period of 1 min (initial rate) was chosen for future
studies.

View larger version (10K):
[in this window]
[in a new window]
|
Fig. 2.
PAH uptake into cells expressing mOAT and
mOAT-myc. a, cells were seeded on transwells, and
directional uptake of PAH (20 µM, 20 min) from either
apical sides (dotted columns) or basal sides
(solid columns) were performed. b,
time course of basolateral uptake of PAH (20 µM). Values
are mean ± S.E. (n = 3).
|
|
To confirm the functional polarization of mOAT at the protein level, we
examined the cellular distribution of mOAT protein by confocal
microscopy, a procedure that is independent of transporter activity.
Previous studies from our laboratory showed that the mOAT-myc protein
retained the functional properties of the native (unmodified) structure
(2). Our current study (Figs. 1 and 2) confirmed these results.
Therefore, the mOAT-myc-transfected cells were chosen for these
studies. mOAT-myc-transfected and vector-transfected
LLC-PK1 cells were grown to confluence, and mOAT protein
was visualized by indirect immunolocalization using confocal laser
scanning microscopy (Fig. 3). A top view
of the epithelial cell layer showed a clear staining of the plasma
membrane of the LLC-PK1-mOAT-myc cells with anti-myc
antibody (Fig. 3a), whereas the vector-transfected
LLC-PK1 cells showed no detectable labeling (Fig.
3b). Examination of the mOAT-myc-tranfected cells at the
plane parallel to the permeable filter revealed that the strongest
immunostaining was confined to the lateral membrane (Fig.
3d) as compared with the basal membrane (Fig.
3e), whereas the apical membrane exhibited only a weak
immunoreactivity (Fig. 3c). Consistent with this result, the
x-z analysis (Fig. 3f) showed that, although the
apical side was weakly stained, the majority of the immunostaining
signal was localized to the basolateral sides. Since the basolateral
membrane is the in vivo site of mOAT function, we have
focused on the uptake studies at this surface.

View larger version (75K):
[in this window]
[in a new window]
|
Fig. 3.
Immunolocalization of mOAT-myc in
LLC-PK1 monolayers by confocal laser-scanning
microscopy. Indirect immunofluorescence (fluorescein
isothiocyanate) picture with anti-myc antibody. a and
b represent top view of the cell monolayer (seeded on
plastic wells), in which a corresponds to
LLC-PK1 transfected with pcDNA3.1( )-mOAT-myc and
b corresponds to LLC-PK1 transfected with
pcDNA3.1( ) alone. c, d, and e
represent optical sections parallel to the plane of the cell layer
(seeded on transwells), in which c corresponds to apical
plane, d corresponds to lateral plane, and e
corresponds to basal plane. f represents optical section
perpendicular to the plane of the cell layer. Arrows
indicate the positions of apical (ap) and basal
(bl) surfaces. The bar is 10 µm.
|
|
Immunoprecipitation of Phosphorylated mOAT-myc
Protein--
SDS-PAGE and autoradiography of immunoprecipitates after
metabolic labeling with [32P]orthophosphate of
LLC-PK1 cells expressing mOAT-myc (Fig.
4) revealed that incubation with 1 µM okadaic acid for 3 h significantly increased the
intensity of a band centered at ~60 kDa (lane
2), the size expected from the estimated molecular mass for
mOAT. The 60-kDa species is absent from immunoprecipitates of cells transfected with pcDNA vector (lane 1) and
had received the same treatment in parallel. Together, these findings
support the conclusion that mOAT protein is a target for direct
phosphorylation by endogenous protein kinases and phosphatases in
stably transfected LLC-PK1 cells.

View larger version (73K):
[in this window]
[in a new window]
|
Fig. 4.
In vivo phosphorylation of mOAT in
LLC-PK1 cells. Cells stably transfected with
pcDNA3.1( ) (lane 1) or
pcDNA3.1( )-mOAT-myc (lane 2) were labeled
with [32P]orthophosphate and incubated with okadaic acid.
Cell lysates were immunoprecipitated with anti-myc antibody,
electrophoresed, and autoradiographed. The arrow indicates
phosphorylated protein.
|
|
Effect of Okadaic Acid on mOAT-myc Phosphorylation and Basolateral
PAH Uptake--
We determined the amount of
[32P]phosphate incorporation into mOAT as a function of
time. As shown in Fig. 5 (a
and b), treatment of LLC-PK1 cells with 1 µM okadaic acid induced a time-dependent augmentation of mOAT phosphorylation. To determine the functional consequences of phosphorylation, basolateral PAH transport rate was
measured in parallel. The elevation in mOAT phosphorylation induced by okadaic acid displays a similar time course to the okadaic
acid-induced down-regulation of [14C]PAH transport (Fig.
5c).

View larger version (13K):
[in this window]
[in a new window]
|
Fig. 5.
Time course of okadaic acid-modulated
phosphorylation of mOAT and PAH uptake. Transfected
LLC-PK1 cells were labeled with
[32P]orthophosphate in phosphate-free DMEM for 1 h
at 37 °C and incubated with 1 µM okadaic acid
(OA) for various times. RIPA extraction,
immunoprecipitation, SDS-PAGE, and autoradiography were performed as
described under "Experimental Procedures." a,
representative autoradiogram of labeling results. b,
quantitation of mOAT labeling. c, 1-min basolateral uptake
of PAH (20 µM) into the cells treated with 1 µM okadaic acid for indicated time periods. Values are
mean ± S.E. (n = 3).
|
|
We then determined the amount of [32P]phosphate
incorporation into mOAT as a function of dose. As shown in Fig.
6 (a and b), the
phosphorylation level of mOAT was elevated with the increase in okadaic
acid concentration. Furthermore, the dose response of phosphorylation
of mOAT correlated closely with the dose response of okadaic
acid-induced down-regulation of [14C]PAH transport (Fig.
6c).

View larger version (21K):
[in this window]
[in a new window]
|
Fig. 6.
Dose response of okadaic acid for the
phosphorylation of mOAT and PAH uptake. Transfected
LLC-PK1 cells were labeled with
[32P]orthophosphate in phosphate-free DMEM for 1 h
at 37 °C and incubated with the indicated concentrations of okadaic
acid for 3 h. RIPA extraction, immunoprecipitation, SDS-PAGE, and
autoradiography were performed as described under "Experimental
Procedures." a, representative autoradiogram of labeling
results. b, quantitation of mOAT labeling. c,
1-min basolateral uptake of PAH (20 µM) into the cells
treated with okadaic acid at the indicated concentrations for 3 h.
Values are mean ± S.E. (n = 3).
|
|
To determine the nature of the phosphorylated residues, we performed
phosphoamino acid analysis of mOAT metabolically labeled with
32P in LLC-PK1 cells and immunoprecipitated
with anti-myc antibody. Our results showed that phosphorylation
of mOAT occurred on one (or more) serine residues, with little
phosphothreonine and no phosphotyrosine detected (Fig.
7).

View larger version (75K):
[in this window]
[in a new window]
|
Fig. 7.
Phosphoamino acid analysis of mOAT.
a, PhosphorImager analysis of
[32P]phospho-mOAT. LLC-PK1 cells stably
transfected with pcDNA3.1( ) alone (lane 1) and
mOAT-myc-pcDNA3.1( ) (lane 2) were incubated with
okadaic acid, metabolically labeled with 32P, and
immonuprecipitated with anti-myc antibody. After SDS-PAGE, the
phosphorylated mOAT was transferred onto PVDF membrane. b,
phosphoamino acid analysis of mOAT. Phosphorylated mOAT from
a was excised from the PVDF membrane and hydrolyzed in
hydrochloric acid, and the resulting phosphoamino acids were separated
with thin layer electrophoresis using pH 1.9 for the first dimension
and pH 3.5 for the second dimension. Autoradiography shows radiolabeled
material comigrating with the phosphoserine (p-Ser)
standard, but not with phosphothreonine (p-Thr) or
phosphotyrosine (p-Tyr). Phosphopeptides resulting from
incomplete hydrolysis are seen as a smear in the second direction. The
origin is indicated.
|
|
Effect of PKC Activation on Basolateral PAH Transport and mOAT-myc
Phosphorylation--
Previous studies have implicated that organic
anion transport may be regulated by PKC (9, 12-15). To test whether
PKC modulates mOAT function, we treated the mOAT-myc-expressing
LLC-PK1 cells with the PKC activator, PMA. Our results
showed that, when cell monolayers were treated with 0.1 µM PMA for 3 h, the mOAT-mediated PAH transport was
decreased by 50% of that of untreated monolayers (Fig.
8a). This PMA- induced
inhibition was time- and concentration-dependent (Fig. 8,
b and c).

View larger version (10K):
[in this window]
[in a new window]
|
Fig. 8.
Effect of PMA on PAH
transport. a, confluent monolayers were incubated for
3 h with or without 0.1 µM PMA added directly to the
culture media. After washing the cells, 1-min basolateral uptake of
[14C]PAH (20 µM) was measured.
b, time-course effect of PMA on [14C]PAH
uptake. Confluent monolayers were incubated for various periods of time
in the absence (open circle) or presence
(solid circles) of 0.1 µM PMA.
After washing the cells, 1-min basolateral uptake of
[14C]PAH (20 µM) was measured. Each point
represents the mean ± S.E. of three experiments. c,
dose dependence of PMA on [14C]PAH uptake. Confluent
monolayers were incubated for 3 h with various concentrations of
PMA (10 nM to 1 µM), and 1-min basolateral
uptake of [14C]PAH (20 µM) was measured.
Values are mean ± S.E. (n = 3).
|
|
To clarify the involvement of PKC in the regulation of PAH transport,
the effect of various PKC activators on the basolateral PAH transport
was studied (Fig. 9). Like PMA, PDBu (the
active phorbol ester) and OAG and indolactam (the non-phorbol ester PKC activators) inhibited the PAH uptake. In contrast, 4 -PDD (the inactive phorbol ester that has no effect on PKC) did not affect PAH
uptake (Fig. 9a). Staurosporine, a potent inhibitor of PKC, blocked the inhibitory effect by PMA (Fig. 9b).

View larger version (17K):
[in this window]
[in a new window]
|
Fig. 9.
Specificity of PMA on PAH transport.
a, confluent monolayers were incubated for 3 h with PKC
activators: active phorbol esters PMA (100 nM), PDBu (10 µM), non-phorbol ester OAG (100 µM), and
indolactam (10 µM), inactive phorbol ester 4 -PDD (100 nM). After washing the cells, 1 min basolateral uptake of
[14C]PAH (20 µM) was measured.
b, cell monolayers were incubated with PMA (0.1 µM) in the absence or presence of staurosporine (1 µM). After washing the cells, 1-min basolateral uptake of
[14C]PAH (20 µM) was measured. Values are
mean ± S.E. (n = 3).
|
|
We then ask whether PKC-dependent inhibition of PAH
transport by PMA also occurs, like okadaic acid, via phosphorylation of mOAT. To answer this question, LLC-PK1 cells were
metabolically labeled with [32P]orthophosphate using the
same experimental conditions that we used for okadaic acid-induced
phosphorylation. As shown in Fig. 10
(a and b), no phosphorylated mOAT was detected in
the presence of various PKC activators. These results suggest that it
is unlikely that phosphorylation of mOAT is responsible for
PKC-dependent inhibition of PAH transport.

View larger version (80K):
[in this window]
[in a new window]
|
Fig. 10.
Effect of PKC modulators on phosphorylation
of mOAT. a, representative autoradiogram of labeling
results in the presence of various concentrations of PMA. Transfected
LLC-PK1 cells were labeled with
[32P]orthophosphate in phosphate-free DMEM for 1 h
at 37 °C and incubated for 3 h with okadaic acid
(OA, 1 µM, positive control) and various
concentrations of PMA. b, representative autoradiogram of
labeling results in the presence of various PKC activators. Transfected
LLC-PK1 cells were labeled with
[32P]orthophosphate in phosphate-free DMEM for 1 h
at 37 °C and incubated for 3 h with okadaic acid
(OA, 1 µM, positive control) and various
concentrations of other PKC activators (10 µM PDBu, 100 µM OAG, 10 µM indolactam. RIPA extraction,
immunoprecipitation, SDS-PAGE, and autoradiography were performed as
described under "Experimental Procedures."
|
|
To further examine the mechanism of the PMA-induced down-regulation of
PAH transport, we determined [14C]PAH uptake at different
substrate concentrations. An Eadie-Hofstee analysis of the derived data
(Fig. 11) showed that pretreatment with
PMA resulted in a decreased Vmax (2.0 ± 0.1 pmol/µg·min with untreated cells, and 1.1 ± 0.1 pmol/µg·min in the presence of PMA) with no significant change in
the affinity for PAH (162 ± 25 µM with untreated
cells, and 123 ± 19 µM in the presence of PMA).
Determination of the protein concentrations in control wells confirmed
that PMA treatment did not change the total protein content of the
cultures (data not shown).

View larger version (12K):
[in this window]
[in a new window]
|
Fig. 11.
Effect of PMA on kinetics of PAH.
Kinetic characteristics were determined at substrate concentration
ranging from 25 to 400 µM (1-min basolateral uptake)
using both cells treated with PMA (0.1 µM)
(solid circles) and untreated cells
(open circles). Transport kinetic values were
calculated using the Eadie-Hofstee transformation. Data presented were
the averaged data from two separate experiments performed with six
replicates per concentration.
|
|
 |
DISCUSSION |
To assess the potential involvement of reversible phosphorylation
for regulation of PAH transport mediated by mOAT, we have studied the
effects of okadaic acid and PKC activators in this process using a
heterologous expression system, the pig proximal tubule-like cell line,
LLC-PK1. LLC-PK1 cells offer several useful advantages for study of the cloned organic anion transporter. 1) They
have many characteristics of proximal renal tubules and have been very
useful in understanding other renal epithelial transport processes and
cellular functions, including organic cation transport (18). 2) This
cell line does not express endogenous PAH transporter (19). Therefore,
expression of mOAT in LLC-PK1 cells will allow us to
dissect the transport characteristics of mOAT in a relevant mammalian
system without the possibly confounding effects of other organic anion
transporters. 3) They possess endogenous PKC and PKA signaling pathways
and provide a good experimental model system for studying the
regulatory mechanisms involving phosphorylation of many transport
process (20, 21). Evidence presented in this study indicated mOAT was
predominantly routed to the basolateral membrane of polarized
LLC-PK1 cells. In accordance with this localization,
substantial mOAT-dependent PAH uptake was detected at the
basolateral surface. This is in agreement with its physiological role
as a basolateral organic anion transporter.
Okadaic acid is a potent inhibitor of protein phosphatase 1 and protein
phosphatase 2A, two of the four major serine/threonine protein
phosphatases in the cytosol of mammalian cells (22). Okadaic acid
readily enters cells, and numerous studies have demonstrated that it
enhances the phosphorylation of many cellular proteins (23, 24),
presumably by preventing dephosphorylation. In this report, we showed
that okadaic acid significantly increased the phosphorylation level of
mOAT and this phosphorylation paralleled in time and concentration the
decrease of basolateral PAH transport activity. Phosphoamino acid
analysis indicated that phosphorylation occurred primarily on serine
residues. These results suggest that the increase in serine
phosphorylation of mOAT by okadaic acid is, at least in part,
responsible for the okadaic acid-induced decrease in basolateral PAH transport.
Many studies indicated that phosphorylation by okadaic acid directly
regulates the activity of proteins such as glucose transporter and
antidepressant-sensitive serotonin transporter (24, 25). In other
cases, okadaic acid acts synergistically with the stimulation of
protein kinases. For example, okadaic acid potentiates the phosphorylation of renal Na+,K+-ATPase by PKC
(26).
Evidence has accumulated to indicate that PKC is involved in organic
anion transport process (9, 12-15). In the present study, we showed
that activation of PKC inhibited mOAT-mediated basolateral PAH
transport, kinetically revealed as a change in Vmax. There are several mechanisms by which PKC
could modulate PAH transport. PKC-induced direct phosphorylation has
been reported (25-27). We therefore asked whether PKC activation, like
okadaic acid, inhibited PAH transport through direct phosphorylation of mOAT, and if so, whether okadaic acid and PKC have synergistic effects.
Our results showed that PMA and other PKC activators failed to elevate
the phosphorylation level of mOAT under various experimental conditions
(Fig. 10, a and b). This suggests that direct
phosphorylation is unlikely to be the cause for PKC-induced inhibition
of PAH transport. Alternatively, PKC activation may induce an
internalization of membrane transporters and/or inhibit the recruitment
of preformed transporters into membrane. Further studies are needed to
clarify these possibilities.
In conclusion, we have demonstrated for the first time that okadaic
acid and PKC activators inhibited mOAT-mediated PAH transport likely
through distinct mechanisms; okadaic acid reduced the transport function by inhibiting phosphoserine dephosphorylation of mOAT, whereas
PKC activators inhibited PAH transport by decreasing the maximum
transport velocity without direct phosphorylation of the transporter
protein. Therefore, the activity of renal organic anion transport is
partially determined by the balance between the activities of competing
serine-threonine kinases, including PKC and at least one other
serine-threonine kinase, and serine-threonine phosphatases, including
PP1 and PP2A.
 |
ACKNOWLEDGEMENTS |
We gratefully thank Dr. Sanjay K. Nigam for
generosity in providing background information for this project and Dr.
Deborah French for support during this work. The reviewer's comments
were most helpful for the revision of this manuscript.
 |
FOOTNOTES |
*
This work was partly supported by New Investigator
Development Award 97-NIDA-019 (to G. Y.) from the American Heart
Association, New York City Affiliate.The costs of publication of this
article were defrayed in part by the
payment of page charges. The article must therefore be hereby marked
"advertisement" in
accordance with 18 U.S.C. Section
1734 solely to indicate this fact.
§
To whom correspondence should be addressed: P. O. Box 1243, Dept.
of Medicine, Mount Sinai School of Medicine, One Gustave L. Levy Pl.,
New York, NY 10029. Tel.: 212-241-7234; Fax: 212-369-5189; E-mail:
gyou@smtplink.mssm.edu.
 |
ABBREVIATIONS |
The abbreviations used are:
mOAT, organic anion
transporter from mouse kidney;
PKC, protein kinase C;
PAH, para-aminohippuric acid;
PDBu, phorbol 12,13-dibutyrate;
RIPA, radioimmune precipitation buffer;
PAGE, polyacrylamide gel
electrophoresis;
DMEM, Dulbecco's modified Eagle's medium;
PMA, phorbol 12-myristate 13-acetate;
PBS, phosphate-buffered saline;
OAG, 1-oleoyl-2-acetyl-sn-glycerol;
PVDF, polyvinylidene
difluoride;
4 -PDD, 4 -phorbol 12,13-didecanoate.
 |
REFERENCES |
| 1.
|
Lopez-Nieto, C. E.,
You, G.,
Bush, K. T.,
Barros, E. J. G.,
Beier, D. R.,
and Nigam, S. K.
(1997)
J. Biol. Chem.
272,
6471-6478[Abstract/Free Full Text]
|
| 2.
|
Kuze, K.,
Graves, P.,
Leahy, A.,
Wilson, P.,
Stuhlmann, H.,
and You, G.
(1999)
J. Biol. Chem.
274,
1519-1524[Abstract/Free Full Text]
|
| 3.
|
Pritchard, J. B.,
and Miller, D. S.
(1993)
Phys. Rev.
73,
765-796[Free Full Text]
|
| 4.
|
Ullrich, K. J.,
and Rumrich, G.
(1988)
Am. J. Physiol.
254,
F453-F462[Abstract/Free Full Text]
|
| 5.
|
Moller, J. V.,
and Sheikh, M. I.
(1983)
Pharmacol. Rev.
34,
315-358[Medline]
[Order article via Infotrieve]
|
| 6.
|
Sweet, D. H.,
Wolff, N. A.,
and Pritchard, J. B.
(1997)
J. Biol. Chem.
272,
30088-30095[Abstract/Free Full Text]
|
| 7.
|
Sekine, T.,
Watanabe, N.,
Hosoyamada, M.,
Kanai, Y.,
and Endou, H.
(1997)
J. Biol. Chem.
272,
18526-18529[Abstract/Free Full Text]
|
| 8.
|
Wolff, N. A.,
Werner, S.,
Burkhardt, S.,
and Burckhardt, G.
(1997)
FEBS Lett.
417,
287-291[CrossRef][Medline]
[Order article via Infotrieve]
|
| 9.
|
Lu, R.,
Chan, B. S.,
and Schuster, V. L.
(1999)
Am J. Physiol.
276,
F295-F303[Abstract/Free Full Text]
|
| 10.
|
Race, J. E.,
Grassl, S. M.,
Williams, W. J.,
and Holtzman, E. J.
(1999)
Biochem. Biophys. Res. Commun.
255,
508-514[CrossRef][Medline]
[Order article via Infotrieve]
|
| 11.
|
Hosoyamada, M.,
Sekine, T.,
Kanai, Y.,
and Endou, H.
(1999)
Am. J. Physiol.
276,
F122-F128[Abstract/Free Full Text]
|
| 12.
|
Hohage, H.,
Lohr, M.,
Querl, U.,
and Greven, J.
(1994)
J. Pharmacol. Exp. Ther.
269,
659-64[Abstract/Free Full Text]
|
| 13.
|
Takano, M.,
Nagai, J.,
Yasuhara, M.,
and Inui, K.
(1996)
Am. J. Physiol.
271,
F469-F475[Abstract/Free Full Text]
|
| 14.
|
Nagai, J.,
Yano, I.,
Hashimoto, Y.,
Takano, M.,
and Inui, K.-I.
(1997)
Am. J. Physiol.
273,
F674-F679[Abstract/Free Full Text]
|
| 15.
|
Miller, D. S.
(1998)
Am. J. Physiol.
274,
F156-F164[Abstract/Free Full Text]
|
| 16.
|
Sanger, F.,
Nicklen, S.,
and Coulson, A. R.
(1977)
Proc. Natl. Acad. Sci. U. S. A.
74,
5463-5467[Abstract/Free Full Text]
|
| 17.
|
Boyle, W. J.,
Van der Geer, P.,
and Hunter, T.
(1991)
Methods Enzymol.
201,
110-149[Medline]
[Order article via Infotrieve]
|
| 18.
|
Grundemann, D.,
Babin-Ebell, J.,
Martel, F.,
Ording, N.,
Schmidt, A.,
and Schomig, E.
(1997)
J. Biol. Chem.
272,
10408-10413[Abstract/Free Full Text]
|
| 19.
|
Hori, R.,
Okamura, M.,
Takayama, A.,
Hirozane, K.,
and Takano, M.
(1993)
Am. J. Physiol.
264,
F975-F980[Abstract/Free Full Text]
|
| 20.
|
Katsura, T.,
Verbavatz, J-M.,
Farinas, J.,
Ma, T.,
Ausiello, D. A.,
Verkman, A. S.,
and Brown, D.
(1995)
Proc. Natl. Acad. Sci. U. S. A.
92,
7212-7216[Abstract/Free Full Text]
|
| 21.
|
Huff, R. A.,
Vaughan, R. A.,
Kuhar, M. J.,
and Uhl, G. R.
(1997)
Neurochemistry
68,
225-32
|
| 22.
|
Cohen, P.,
Holmes, C. F.,
and Tsukitani, Y.
(1990)
Trends Biochem. Sci.
15,
98-102[CrossRef][Medline]
[Order article via Infotrieve]
|
| 23.
|
Baggio, B.,
Bordin, L.,
Clari, G.,
Gambaro, G.,
and Moret, V.
(1993)
Biochim. Biophys. Acta
1148,
157-160[Medline]
[Order article via Infotrieve]
|
| 24.
|
Lawrence, J. C., Jr.,
Hiken, J. F.,
and James, D. E.
(1990)
J. Biol. Chem.
265,
19768-19776[Abstract/Free Full Text]
|
| 25.
|
Ramamoorthy, S.,
Giovanetti, E.,
Qian, Y.,
and Blakely, R. D.
(1998)
J. Biol. Chem.
273,
2458-2466[Abstract/Free Full Text]
|
| 26.
|
Li, D.,
Cheng, S. X. J.,
Fisone, G.,
Caplan, M. J.,
Ohtomo, Y.,
and Aperia, A.
(1998)
Am. J. Physiol.
275,
863-869
|
| 27.
|
Vaughan, R. A.,
Huff, R. A.,
Uhl, G. R.,
and Kuhar, M. J.
(1997)
J. Biol. Chem.
272,
15541-15546[Abstract/Free Full Text]
|
| 28.
|
Yip, J. W.,
Ko, W. H.,
Viberti, G.,
Huganir, R. L.,
Donowitz, M.,
and Tse, C.-M.
(1997)
J. Biol. Chem.
272,
18473-18480[Abstract/Free Full Text]
|
| 29.
|
Corey, J. L.,
Davidson, N.,
Lester, H. A.,
Brecha, N.,
and Quick, M. W.
(1994)
J. Biol. Chem.
269,
14759-14767[Abstract/Free Full Text]
|
| 30.
|
Brown, D.,
and Stow, J. L.
(1996)
Physiol. Rev.
76,
245-297[Abstract/Free Full Text]
|
| 31.
|
Sweet, D. H.,
Miller, D. S.,
and Pritchard, J. B.
(1999)
Am. J. Physiol.
276,
F864-F873[Abstract/Free Full Text]
|
| 32.
|
Tojo, A.,
Sekine, T.,
Nakajima, N.,
Hosoyamada, M.,
Kanai, Y.,
Kimura, K.,
and Endou, H.
(1999)
Am. Soc. Nephrol.
10,
464-471[Abstract/Free Full Text]
|
Copyright © 2000 by The American Society for Biochemistry and Molecular Biology, Inc.

CiteULike Complore Connotea Del.icio.us Digg Reddit Technorati What's this?
This article has been cited by other articles:

|
 |

|
 |
 
S. Li, P. Duan, and G. You
Regulation of human organic anion transporter 1 by ANG II: involvement of protein kinase C{alpha}
Am J Physiol Endocrinol Metab,
February 1, 2009;
296(2):
E378 - E383.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
S. A. Barros, C. Srimaroeng, J. L. Perry, R. Walden, N. Dembla-Rajpal, D. H. Sweet, and J. B. Pritchard
Activation of Protein Kinase C{zeta} Increases OAT1 (SLC22A6)- and OAT3 (SLC22A8)-mediated Transport
J. Biol. Chem.,
January 30, 2009;
284(5):
2672 - 2679.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
Q. Zhang, M. Hong, P. Duan, Z. Pan, J. Ma, and G. You
Organic Anion Transporter OAT1 Undergoes Constitutive and Protein Kinase C-regulated Trafficking through a Dynamin- and Clathrin-dependent Pathway
J. Biol. Chem.,
November 21, 2008;
283(47):
32570 - 32579.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
S. K. Banu, J. Lee, M. C. Satterfield, T. E. Spencer, F. W. Bazer, and J. A. Arosh
Molecular Cloning and Characterization of Prostaglandin (PG) Transporter in Ovine Endometrium: Role for Multiple Cell Signaling Pathways in Transport of PGF2{alpha}
Endocrinology,
January 1, 2008;
149(1):
219 - 231.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
A. G. Aslamkhan, D. M. Thompson, J. L. Perry, K. Bleasby, N. A. Wolff, S. Barros, D. S. Miller, and J. B. Pritchard
The flounder organic anion transporter fOat has sequence, function, and substrate specificity similarity to both mammalian Oat1 and Oat3
Am J Physiol Regulatory Integrative Comp Physiol,
December 1, 2006;
291(6):
R1773 - R1780.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
T. Sekine, H. Miyazaki, and H. Endou
Molecular physiology of renal organic anion transporters
Am J Physiol Renal Physiol,
February 1, 2006;
290(2):
F251 - F261.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
M. Hong, W. Xu, T. Yoshida, K. Tanaka, D. J. Wolff, F. Zhou, M. Inouye, and G. You
Human Organic Anion Transporter hOAT1 Forms Homooligomers
J. Biol. Chem.,
September 16, 2005;
280(37):
32285 - 32290.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
W. Jiang, O. Prokopenko, L. Wong, M. Inouye, and O. Mirochnitchenko
IRIP, a New Ischemia/Reperfusion-Inducible Protein That Participates in the Regulation of Transporter Activity
Mol. Cell. Biol.,
August 1, 2005;
25(15):
6496 - 6508.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
P. Chandra, P. Zhang, and K. L. R. Brouwer
Short-term regulation of multidrug resistance-associated protein 3 in rat and human hepatocytes
Am J Physiol Gastrointest Liver Physiol,
June 1, 2005;
288(6):
G1252 - G1258.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
S. Soodvilai, V. Chatsudthipong, K. K. Evans, S. H. Wright, and W. H. Dantzler
Acute regulation of OAT3-mediated estrone sulfate transport in isolated rabbit renal proximal tubules
Am J Physiol Renal Physiol,
November 1, 2004;
287(5):
F1021 - F1029.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
S. H. Wright and W. H. Dantzler
Molecular and Cellular Physiology of Renal Organic Cation and Anion Transport
Physiol Rev,
July 1, 2004;
84(3):
987 - 1049.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
K. Tanaka, W. Xu, F. Zhou, and G. You
Role of Glycosylation in the Organic Anion Transporter OAT1
J. Biol. Chem.,
April 9, 2004;
279(15):
14961 - 14966.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
C. Sauvant, D. Hesse, H. Holzinger, K. K. Evans, W. H. Dantzler, and M. Gekle
Action of EGF and PGE2 on basolateral organic anion uptake in rabbit proximal renal tubules and hOAT1 expressed in human kidney epithelial cells
Am J Physiol Renal Physiol,
April 1, 2004;
286(4):
F774 - F783.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
S. A. Eraly, K. T. Bush, R. V. Sampogna, V. Bhatnagar, and S. K. Nigam
The Molecular Pharmacology of Organic Anion Transporters: from DNA to FDA?
Mol. Pharmacol.,
March 1, 2004;
65(3):
479 - 487.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
C. Sauvant, H. Holzinger, and M. Gekle
Short-Term Regulation of Basolateral Organic Anion Uptake in Proximal Tubular Opossum Kidney Cells: Prostaglandin E2 Acts via Receptor-Mediated Activation of Protein Kinase A
J. Am. Soc. Nephrol.,
December 1, 2003;
14(12):
3017 - 3026.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
N. A. Wolff, K. Thies, N. Kuhnke, G. Reid, B. Friedrich, F. Lang, and G. Burckhardt
Protein Kinase C Activation Downregulates Human Organic Anion Transporter 1-Mediated Transport through Carrier Internalization
J. Am. Soc. Nephrol.,
August 1, 2003;
14(8):
1959 - 1968.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
D. H. Sweet, L. M. S. Chan, R. Walden, X.-P. Yang, D. S. Miller, and J. B. Pritchard
Organic anion transporter 3 (Slc22a8) is a dicarboxylate exchanger indirectly coupled to the Na+ gradient
Am J Physiol Renal Physiol,
April 1, 2003;
284(4):
F763 - F769.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
A. Bahn, M. Knabe, Y. Hagos, M. Rodiger, S. Godehardt, D. S. Graber-Neufeld, K. K. Evans, G. Burckhardt, and S. H. Wright
Interaction of the Metal Chelator 2,3-Dimercapto-1-propanesulfonate with the Rabbit Multispecific Organic Anion Transporter 1 (rbOAT1)
Mol. Pharmacol.,
November 1, 2002;
62(5):
1128 - 1136.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
C. Sauvant, H. Holzinger, and M. Gekle
Short-Term Regulation of Basolateral Organic Anion Uptake in Proximal Tubular OK cells: EGF Acts via MAPK, PLA2, and COX1
J. Am. Soc. Nephrol.,
August 1, 2002;
13(8):
1981 - 1991.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
G. L. Guo and C. D. Klaassen
Protein Kinase C Suppresses Rat Organic Anion Transporting Polypeptide 1- and 2-Mediated Uptake
J. Pharmacol. Exp. Ther.,
November 1, 2001;
299(2):
551 - 557.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
D. H. Sweet, K. T. Bush, and S. K. Nigam
The organic anion transporter family: from physiology to ontogeny and the clinic
Am J Physiol Renal Physiol,
August 1, 2001;
281(2):
F197 - F205.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
C. Sauvant, H. Holzinger, and M. Gekle
Modulation of the Basolateral and Apical Step of Transepithelial Organic Anion Secretion in Proximal Tubular Opossum Kidney Cells. ACUTE EFFECTS OF EPIDERMAL GROWTH FACTOR AND MITOGEN-ACTIVATED PROTEIN KINASE
J. Biol. Chem.,
April 27, 2001;
276(18):
14695 - 14703.
[Abstract]
[Full Text]
[PDF]
|
 |
|
Copyright © 2000 by the American Society for Biochemistry and Molecular Biology.
|
Advertisement
Advertisement
|